Page 261 - Vitamin D and Cancer

248 C.M. Barnett and T.M. Beer

150. Bower M, Colston KW, Stein RC et al (1991) Topical calcipotriol treatment in advanced
breast cancer. Lancet 337:701–702
151. Liu G, Oettel K, Ripple G et al (2002) Phase I trial of 1alpha-hydroxyvitamin d(2) in patients
with hormone refractory prostate cancer. Clin Cancer Res 8:2820–2827
152. Attia S, Eickhoff J, Wilding G et al (2008) Randomized, double-blinded phase II evaluation of
docetaxel with or without doxercalciferol in patients with metastatic, androgen- sindependent
prostate cancer. Clin Cancer Res 14:2437–2443
153. Wieder R, Novick SC, Hollis BW et al (2003) Pharmacokinetics and safety of ILX23–7553, a
non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies.
Invest New Drugs 21:445–452
154. Schwartz GG, Hall MC, Stindt D et al (2005) Phase I/II study of 19-nor-1alpha-25-
dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin
Cancer Res 11:8680–8685
155. Kim RH, Li JJ, Ogata Y et al (1996) Identification of a vitamin D3-response element that
overlaps a unique inverted TATA box in the rat bone sialoprotein gene. Biochem J
318(Pt 1):219–226
156. Falzon M (1996) DNA sequences in the rat parathyroid hormone-related peptide gene
responsible for 1, 25-dihydroxyvitamin D3-mediated transcriptional repression. Mol
Endocrinol 10:672–681
157. Gill RK, Christakos S (1993) Identification of sequence elements in mouse calbindin-D28k
gene that confer 1, 25-dihydroxyvitamin D3- and butyrate-inducible responses. Proc Natl
Acad Sci USA 90:2984–2988
158. Kitazawa R, Kitazawa S (2002) Vitamin D(3) augments osteoclastogenesis via vitamin
D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun
290:650–655
159. Matilainen M, Malinen M, Saavalainen K et al (2005) Regulation of multiple insulin-like
growth factor binding protein genes by 1alpha, 25-dihydroxyvitamin D3. Nucleic Acids Res
33:5521–5532
160. Peng L, Malloy PJ, Feldman D (2004) Identification of a functional vitamin D response ele-
ment in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol
18:1109–1119
161. Polly P, Carlberg C, Eisman JA et al (1996) Identification of a vitamin D3 response element
in the fibronectin gene that is bound by a vitamin D3 receptor homodimer. J Cell Biochem
60:322–333
162. Cao X, Ross FP, Zhang L et al (1993) Cloning of the promoter for the avian integrin beta 3
subunit gene and its regulation by 1, 25-dihydroxyvitamin D3. J Biol Chem
268:27371–27380
163. Bikle DD, Ng D, Oda Y et al (2002) The vitamin D response element of the involucrin gene
mediates its regulation by 1, 25-dihydroxyvitamin D3. J Invest Dermatol 119:1109–1113
164. Candeliere GA, Jurutka PW, Haussler MR et al (1996) A composite element binding the
vitamin D receptor, retinoid X receptor alpha, and a member of the CTF/NF-1 family of
transcription factors mediates the vitamin D responsiveness of the c-fos promoter. Mol Cell
Biol 16:584–592
165. Xie Z, Bikle DD (1998) Differential regulation of vitamin D responsive elements in normal
and transformed keratinocytes. J Invest Dermatol 110:730–733
166. McGaffin KR, Chrysogelos SA (2005) Identification and characterization of a response ele-
ment in the EGFR promoter that mediates transcriptional repression by 1, 25-dihydroxyvitamin
D3 in breast cancer cells. J Mol Endocrinol 35:117–133
167. Drissi H, Pouliot A, Koolloos C et al (2002) 1, 25-(OH)2-vitamin D3 suppresses the bone-
related Runx2/Cbfa1 gene promoter. Exp Cell Res 274:323–333
168. Quelo I, Machuca I, Jurdic P (1998) Identification of a vitamin D response element in the proximal
promoter of the chicken carbonic anhydrase II gene. J Biol Chem 273:10638–10646
169. Seoane S, Alonso M, Segura C et al (2002) Localization of a negative vitamin D response
sequence in the human growth hormone gene. Biochem Biophys Res Commun 292:250–255